GlassScriptPhysician profile
Salma Balbas
NPI 1194314104
$7,133.22
in general payments reported to CMS, 2019-2025
26 companies · $2,013 in 2025
The $2,013 reported for 2025 was more than what 93% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $525 · 2022: $1,135 · 2023: $760 · 2024: $2,700 · 2025: $2,013.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,299 · Education: $174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,298.93 |
| Education | $173.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,770.07 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $693.29 | 2023-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $582.44 | 2022-2024 | |
| Janssen Biotech, INC. | $453.65 | 2022-2025 | Tremfya, Simponi Aria, Simponi |
| E.R. Squibb & Sons, L.L.C. | $423.76 | 2023-2025 | Sotyktu |
| Lilly USA, LLC | $263.28 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Mayne Pharma Commercial LLC | $244.99 | 2024-2025 | |
| Galderma Laboratories, L.P. | $202.82 | 2024-2025 | Nemluvio, Aklief |
| Arcutis Biotherapeutics, INC. | $182.06 | 2023-2025 | Zoryve |
| Incyte Corporation | $174.54 | 2022-2025 | Opzelura |
| Ucb, INC. | $157.02 | 2021-2025 | Bimzelx |
| Pfizer INC. | $144.55 | 2021-2025 | |
| Amgen INC. | $130.20 | 2023-2025 | Otezla |
| Novartis Pharmaceuticals Corporation | $120.83 | 2021-2025 | |
| Genentech USA, INC. | $112.09 | 2021-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $108.78 | 2024 | Vtama |
| Sun Pharmaceutical Industries INC. | $80.52 | 2025 | |
| Verrica Pharmaceuticals INC. | $63.92 | 2024-2025 | Ycanth |
| Janssen Scientific Affairs, LLC | $60.00 | 2022 | |
| Stemline Therapeutics INC. | $30.13 | 2025 | Elzonris |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $24.82 | 2025 | Jublia, Cabtreo |
| Paratek Pharmaceuticals, INC. | $24.20 | 2024 | Nuzyra |
| Vyne Pharmaceuticals INC. | $23.31 | 2021 | |
| Biofrontera INC. | $21.19 | 2022 | |
| Solta Medical, A Division of Bausch Health US, LLC | $20.70 | 2024 | Fraxel |
| Boston Scientific Corporation | $20.06 | 2025 | Wavewriter Alpha Prime 16 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Salma Balbas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.